CD19-targeted chimeric receptor antigen (CAR)-T cell therapy has shown remarkable
clinical efficacy in the treatment of relapsed or refractory (R/R) B-cell malignancies …

CD20 located predominantly on the B cells plays a crucial role in their development,
differentiation, and activation, and serves as a key therapeutic target for the treatment of B …

During the past few decades, CD19 has been at the center of various scientific/translational
endeavors to develop targeted therapeutics against B-cell malignancies. Due to the …

Immunotherapeutic agents play an increasingly important role in the treatment of B-cell
malignancies. CD19 and CD20 are common targets for lymphoid malignancies, though …

Background CD19 chimeric antigen receptor (CAR) therapy has achieved impressive
success in relapsed or refractory (R/R) B-cell malignancies, but relapse due to antigen …

Immunotherapy is a hot area in cancer treatment, and one of the keys to this therapy is the
identification of the right tumour-associated or tumour-specific antigen. Cluster of …

In recent years, the excellent curative effect of CD19‐specific chimeric antigen receptor
(CAR) T‐cell therapy has brought hope to patients with relapsing or refractory B‐cell …

Chimeric-antigen-receptor (CAR) T-cell therapy for CD19-expressing B-cell malignancies is
already widely adopted in clinical practice. On the other hand, the development of CAR-T …

CD22 is an attractive target for the development of immunotherapeutic approaches for the
therapy of B-cell malignancies. In particular, an m971 antibody-derived, second generation …

Effective immunotherapies for T-cell malignancies are lacking. We devised a novel
approach based on chimeric antigen receptor (CAR)–redirected T lymphocytes. We selected …